# EDGAR Filing Document

**Accession Number:** 0001817640
**File Stem:** 0001213900-25-077443
**Filing Date:** 2025-8
**Character Count:** 17388
**Document Hash:** d759d3843bc76f0486326cd7b40e2499
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-077443.hdr.sgml**: 20250815

**ACCESSION NUMBER**: 0001213900-25-077443

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250814

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250815

**DATE AS OF CHANGE**: 20250815

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Breeze Holdings Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001817640
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39718
- **FILM NUMBER:** 251224630

**BUSINESS ADDRESS:**
- **STREET 1:** 955 W. JOHN CARPENTER FWY.
- **STREET 2:** STE. 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039
- **BUSINESS PHONE:** 619-500-7747

**MAIL ADDRESS:**
- **STREET 1:** 955 W. JOHN CARPENTER FWY.
- **STREET 2:** STE. 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 14, 2025**

**BREEZE HOLDINGS ACQUISITION CORP.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39718** | **85-1849315** |
| **(State or other jurisdiction of** | **(Commission File Number)** | **(IRS Employer** |
| **incorporation or organization)** |  | **Identification Number)** |

---

**955 W. John Carpenter Freeway, Suite 100-929 Irving, TX 75039**

**(Address of principal executive offices)**

**(888) 273-9001**

**Registrant's telephone number, including area code**

**Not Applicable**

**(Former name or former address, if changed since last report)**

 ****

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on<br> which registered |
| Common Stock, $0.0001 par value per share | BRZH | OTCQX tier of the OTC Markets Group Inc. |
| Rights exchangeable into one-twentieth of one share of common stock | BRZHR | OTCQB tier of the OTC Markets Group Inc. |
| Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per whole share | BRZHW | OTCQB tier of the OTC Markets Group Inc. |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

A Special Meeting of Stockholders (the "<u>Special Meeting</u>") of Breeze Holdings Acquisition Corp. (the "<u>Company</u>") was held via webcast on August 14, 2025, at 10:00 a.m. Eastern Time. The number of shares of common stock that voted on matters presented at the Special Meeting was 3,128,495, representing 93.0% of the 3,364,413 shares of common stock issued and outstanding, and entitled to vote as of July 11, 2025, the record date for the Special Meeting.

Each of the proposals described below was approved by the Company's stockholders of record. In connection with the special meeting, 49,715 shares of the Company's common stock were redeemed (the "<u>Redemption</u>"), with 3,314,698 shares of Common Stock remaining outstanding after the Redemption; 224,413 shares of Common Stock remaining outstanding after the Redemption are shares issued in connection with our initial public offering (the "<u>Public Shares</u>").

The following is a list of matters considered and approved by the Company's stockholders at the Special Meeting:

&nbsp;&nbsp;&nbsp;&nbsp;1. **The Business Combination Proposal** — At the meeting, the vote to consider and adopt the Merger Agreement and Plan of Reorganization,
dated September 24, 2024 (as may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement"),
by and among (i) Breeze, (ii) YD Bio Limited, a Cayman Islands exempted company ("Pubco"), (iii) Breeze Merger Sub, Inc.,
a Delaware corporation and which will be a direct, wholly-owned subsidiary of Pubco ("Breeze Merger Sub"), (iv) BH Biopharma
Merger Sub Limited, a Cayman Islands exempted company ("Company Merger Sub," with Company Merger Sub and Breeze Merger Sub
together referred to herein as the "Merger Subs"), and (v) YD Biopharma Limited, a Cayman Islands exempted company ("YD
Biopharma"), was as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Votes For: | 3,127,474 | Votes Against: | 1,000 | Votes Withheld: | 21 |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. **The Charter Proposal** — At the meeting, the vote to consider and vote upon a proposal to approve and adopt the proposed second amended
and restated memorandum and articles of association of Pubco, was as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Votes For: | 3,127,474 | Votes Against: | 1,000 | Votes Withheld: | 21 |

---

&nbsp;&nbsp;&nbsp;&nbsp;3. **The Advisory Charter Proposals** — To consider
and vote upon, on a non-binding advisory basis, proposals to approve certain provisions contained in the Proposed Charter which differ
from the provisions of the Existing Charter, presented separately in accordance with the United States Securities and Exchange Commission
("SEC") requirements (the "Advisory Charter Proposals") (Proposal No. 3).

**Advisory Charter Proposal 3(a)** — To provide that Pubco shall have an authorized share capital of 500,000,000 Ordinary Shares, par value US$0.0001 per share.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Votes For: | 3,127,481 | Votes Against: | 1,010 | Votes Withheld:<sub>4</sub> |

---

**Advisory Charter Proposal 3(b)** — To provide that any amendment to the Proposed Charter will require the approval of the holders of at least a two-third majority of the votes cast by, or on behalf of the shareholders who (being entitled to do so) vote in person or by proxy at the general meeting of Pubco.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Votes For: | 3,127,126 | Votes Against: | 1,364 | Votes Withheld:<sub>5</sub> |

---

**Advisory Charter Proposal 3(c)** — To remove the blank check provisions from the Existing Charter.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Votes For: | 3,127,490 | Votes Against: | 1,005 | Votes Withheld:<sub>0</sub> |

---

**Advisory Charter Proposal 3(d)** — To change the classification of the Pubco Board from two classes to three classes, with each class elected for a staggered term, as well as with each class consisting, as nearly as may be possible, of one third of the total number of directors constituting the whole board.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Votes For: | 3,127,091 | Votes Against: | 1,374 | Votes Withheld: | 30 |

---

&nbsp;&nbsp;&nbsp;&nbsp;4. **The Incentive Plan Proposal** — At the meeting, the vote to consider and vote upon the Pubco Incentive Plan, a copy of which is attached
to the proxy statement/prospectus as Annex C (Proposal No. 4), was as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Votes For: | 3,125,277 | Votes Against: | 2,393 | Votes Withheld: | 825 |

---

&nbsp;&nbsp;&nbsp;&nbsp;5. **The Redemption Limitation Amendment Proposal** — At the meeting, the vote to consider and vote upon a proposal to approve an amendment
to the Company's Amended and Restated Certificate of Incorporation, as amended to date, in the form set forth in Annex G to the
accompanying proxy statement/prospectus, to eliminate the limitation that Breeze, or any entity that succeeds Breeze as a public company,
may not redeem Company Shares (as defined therein) in an amount that would cause the net tangible assets of Breeze, or any entity that
succeeds Breeze as a public company, to be less than $5,000,001 (the "Redemption Limitation") (Proposal No. 5), was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Votes For: | 3,128,464 | Votes Against:<sub>10</sub> | Votes Withheld: | 21 |

---

**Item 8.01. Other Events.**

Attached hereto as Exhibit 99.1, and filed herewith, is a copy of the Company's press release regarding the matters described in Item 5.07 of this Current Reporting on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release of Breeze Holdings Acquisition Corp. dated August 15, 2025](ea025345801ex99-1_breeze.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **BREEZE HOLDINGS ACQUISITION CORP.** | **BREEZE HOLDINGS ACQUISITION CORP.** |
| By: | /s/ J. Douglas Ramsey |
| Name: | J. Douglas Ramsey |
| Title: | Chief Executive Officer and Chief Financial Officer |

---

Dated: August 15, 2025

## Exhibit 99.1

**Exhibit 99.1**

**BREEZE HOLDINGS ACQUISITION CORP. SHAREHOLDERS APPROVE BUSINESS<br> COMBINATION WITH YD BIOPHARMA LIMITED**

*Transaction Expected to Close in the Coming Days*

 

*Combined Company to be Named YD Bio Limited and Expected<br> to Trade on Nasdaq Under Ticker Symbol "YDES"*

**Irving, Texas, August 15, 2025** — Breeze Holdings Acquisition Corp. ("Breeze") (OTCQX: BRZH; OTCQB: BRZHR, BRZHW), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the "Business Combination") with YD Biopharma Limited ("YD Biopharma"), a Taiwan–based biopharmaceutical company dedicated to developing, manufacturing and commercializing innovative vaccines and therapeutic biologics for infectious diseases and other indications.

The special meeting of stockholders was held on August 14, 2025. Holders of 3,128,495 shares were represented in person or by proxy, constituting a quorum. The Business Combination Proposal was approved by a vote of 3,127,474 shares in favor, 1,000 shares against, and 21 abstentions. All other proposals necessary to complete the transaction, including amendments to the charter of the combined company and approval of the Pubco Incentive Plan, were also approved.

A replay of the meeting is available at www.virtualshareholdermeeting.com/BRZH2025SM2.

Upon closing, the combined company will operate as YD Bio Limited and its ordinary shares are expected to begin trading on the Nasdaq Stock Market under the new ticker symbol "YDES." The closing is expected to occur within the next two weeks, subject to the satisfaction of customary closing conditions.

**Advisors**

ArentFox Schiff LLP is acting as legal advisor to YD Biopharma. I-Bankers Securities, Inc. is acting as financial advisor to Breeze. Woolery & Co. PLLC is acting as legal advisor to Breeze. Ogier is acting as Cayman Islands legal advisor to Breeze.

**About YD Biopharma Limited**

YD Biopharma Limited is a clinical-stage biopharmaceutical company focusing on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. Through continuous effort and innovation, the Company has also become a recognized supplier of clinical trial drugs and has begun developing and supplying post-market auxiliary products.

For more information, please visit www.yd-biopharma.com.

**About Breeze Holdings Acquisition Corp.**

Breeze is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses or entities.

**Cautionary Note Regarding Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements regarding the anticipated benefits and impact of the proposed transaction on the combined company's business and future financial and operating results, the anticipated timing of closing of the proposed transaction, the anticipated growth of the industries and markets in which YD Biopharma competes, the success and customer acceptance of YD Biopharma's product and service offerings and other aspects of YD Biopharma's operations, plans, objectives, opportunities, expectations or operating results, the expected ownership structure of the combined company and the likelihood and ability of the parties to successfully consummate the proposed transaction. Words such as "may," "should," "will," "believe," "expect," "anticipate," "intend," "estimated," "target," "project," and similar phrases or words of similar meaning that denote future expectations or intent regarding the combined company's financial results, operations and other matters are intended to identify forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Such forward-looking statements are based upon the current beliefs and expectations of management and are inherently subject to significant business, economic and competitive risks, uncertainties and other factors, both known and unknown, which are difficult to predict and generally beyond our control and that may cause actual results and the timing of future events to differ materially from the results and timing of future events anticipated by the forward-looking statements in this press release.

The forward-looking statements contained in this press release are also subject to additional risks, uncertainties and factors, including those described in Breeze Holdings' most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other documents filed or to be filed with the SEC by Breeze Holdings from time to time. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. The forward-looking statements included in this press release are made only as of the date hereof, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date hereof. Forecasts and estimates regarding YD Biopharma's industry and end markets are based on sources we believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part. Annualized, pro forma, projected and estimated numbers are used for illustrative purposes only, are not forecasts and may not reflect actual results.

**No Offer or Solicitation**

This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any proxy, consent, vote or approval with respect to any securities in respect of the proposed transaction and is not a substitute for the Proxy Statement/Prospectus or any other document that Breeze Holdings may file with the SEC or send to Breeze Holdings' or YD Biopharma's stockholders in connection with the proposed transaction. No offer, sale, issuance or transfer of securities shall be made in any jurisdiction in which such offer, sale, issuance or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

**Contacts:**

**YD Biopharma Limited**

Robert Chiu

bobc95@yd-biopharma.com

**Investor Relations**

Jackson Lin

Lambert by LLYC

Tel: +1 (646) 717-4593

Email: jian.lin@llyc.global

**Breeze Holdings Acquisition Corp.**

**Investor Relations**

Cody Slach

Gateway Group

(949) 574-3860

BREZ@gateway-grp.com